In the HCC cells, HBO1 shRNA resulted in robust viability (CCK-8 OD) reduction (Fig. 2J), proliferation inhibition (reduced nuclear EdU ratio, Fig. 2K) and cell migration decrease (results quantified in Fig. 2L). This evidence concerns the gene KAT7 and hepatocellular carcinoma.